Skip to main content
Prostate Cancer Principles and Practice

Management of biochemical recurrence following radiation therapy

Publication ,  Chapter
Collins, TS; George, DJ
January 1, 2005

The introduction and use of the prostate-specific antigen (PSA) test has had a profound impact on the diagnosis and management of patients with prostate cancer. Prostate-specific antigen has gained wide acceptance as a screening tool for early detection of prostate cancer, yet it was originally developed as a tumor marker.1 As a tumor marker, PSA has demonstrated exceptional sensitivity and specificity for disease progression. One of the most important applications of PSA is its use in patients following definitive local therapy.

Duke Scholars

Publication Date

January 1, 2005

Start / End Page

865 / 873
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Collins, T. S., & George, D. J. (2005). Management of biochemical recurrence following radiation therapy. In Prostate Cancer Principles and Practice (pp. 865–873).
Collins, T. S., and D. J. George. “Management of biochemical recurrence following radiation therapy.” In Prostate Cancer Principles and Practice, 865–73, 2005.
Collins TS, George DJ. Management of biochemical recurrence following radiation therapy. In: Prostate Cancer Principles and Practice. 2005. p. 865–73.
Collins, T. S., and D. J. George. “Management of biochemical recurrence following radiation therapy.” Prostate Cancer Principles and Practice, 2005, pp. 865–73.
Collins TS, George DJ. Management of biochemical recurrence following radiation therapy. Prostate Cancer Principles and Practice. 2005. p. 865–873.

Publication Date

January 1, 2005

Start / End Page

865 / 873